Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Powell on Tumor Mutational Burden in Ovarian Cancer

Matthew Powell, MD
Published: Tuesday, Oct 23, 2018



Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses tumor mutational burden (TMB) in ovarian cancer.

A compilation of several trials across various tumor types suggested that TMB may be a good predictor of response, says Powell. Though it is being investigated in ovarian cancer, Powell adds that it is not yet ready for clinical application in the malignancy.

The biggest application of TMB has been in lung cancer. In June 2018, the FDA accepted a supplemental biologics license application (sBLA) for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the frontline treatment of patients with advanced non–small cell lung cancer (NSCLC) with TMB ≥10 mutations per megabase. The sBLA is based on data from the CheckMate-227 trial.

Additionally, data from the CheckMate-586 trial indicated that TMB was predictive of patients with NSCLC who were more likely to experience benefit from the frontline combination of nivolumab and ipilimumab. The combination showed response rates of 9% with TMB less than 5, 15% with TMB 5 to 10, 44% with TMB ≥10, and 39% for those with TMB levels of ≥15.


Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses tumor mutational burden (TMB) in ovarian cancer.

A compilation of several trials across various tumor types suggested that TMB may be a good predictor of response, says Powell. Though it is being investigated in ovarian cancer, Powell adds that it is not yet ready for clinical application in the malignancy.

The biggest application of TMB has been in lung cancer. In June 2018, the FDA accepted a supplemental biologics license application (sBLA) for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the frontline treatment of patients with advanced non–small cell lung cancer (NSCLC) with TMB ≥10 mutations per megabase. The sBLA is based on data from the CheckMate-227 trial.

Additionally, data from the CheckMate-586 trial indicated that TMB was predictive of patients with NSCLC who were more likely to experience benefit from the frontline combination of nivolumab and ipilimumab. The combination showed response rates of 9% with TMB less than 5, 15% with TMB 5 to 10, 44% with TMB ≥10, and 39% for those with TMB levels of ≥15.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x